280 related articles for article (PubMed ID: 24319229)
1. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
2. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Zhang SJ; Abdel-Wahab O
Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
[TBL] [Abstract][Full Text] [Related]
3. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
5. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J; Mead AJ
Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
[TBL] [Abstract][Full Text] [Related]
7. Mutant calreticulin in myeloproliferative neoplasms.
How J; Hobbs GS; Mullally A
Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
[TBL] [Abstract][Full Text] [Related]
8. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
9. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
11. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
12. Genetics of the myeloproliferative neoplasms.
Abdel-Wahab O
Curr Opin Hematol; 2011 Mar; 18(2):117-23. PubMed ID: 21307773
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics in Myeloproliferative Neoplasms.
McPherson S; McMullin MF; Mills K
J Cell Mol Med; 2017 Sep; 21(9):1660-1667. PubMed ID: 28677265
[TBL] [Abstract][Full Text] [Related]
14. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
15. Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.
Reuther GW
Am J Cancer Res; 2011; 1(6):752-62. PubMed ID: 22016825
[TBL] [Abstract][Full Text] [Related]
16. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
17. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
19. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
20. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]